Asterias Biotherapeutics Inc. | |
Stock Exchange | NYSE |
EPS |
$0.43 |
Market Cap |
$74.94 M |
Shares Outstanding |
55.51 M |
Public Float |
33.08 M |
Address |
6300 Dumbarton Circle Fremont California 94555 United States |
Employees | - |
Website | http://www.asteriasbiotherapeutics.com |
Updated | 09/14/2018 |
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. |